Arcturus Therapeutics Ltd (NASDAQ: ARCT) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating.
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- InnovationRx: The 30 Under 30 Healthcare List [Forbes]Forbes
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults [Yahoo! Finance]Yahoo! Finance
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsPR Newswire
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.MarketBeat
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsBusiness Wire
ARCT
Earnings
- 11/14/23 - Beat
ARCT
Sec Filings
- 11/14/23 - Form 10-Q
- 11/14/23 - Form 8-K
- 11/3/23 - Form 4
- ARCT's page on the SEC website